

PECA labs

Investor Update: MASA Valve Successful First-in-Human Implant

It is my great honor to inform you that MASA Valve, our novel fully-polymeric pulmonary valved conduit, has been successfully implanted in an historic first-in-human case. The surgery was conducted at Children's Hospital of Philadelphia as treatment for an infant suffering from Tetralogy of Fallot. Early data shows successful valve function; the patient has experienced an excellent recovery and was discharged from the hospital today.

This first-in-human implant represents a significant milestone in PECA Labs' goal of leveraging our proprietary polymer material platform to revolutionize artificial heart valves. To our knowledge, PECA Labs is the only start-up to have both an FDA-cleared implantable device and to have brought a novel valve material through a first-in-human implant. With this landmark event PECA Labs has now brought the MASA Valve one step closer to being the first ever commercially-available polymeric heart valve.

This major achievement is a reflection of not only the hard work and dedication of our team, but of the unwavering support of all our investors and advisors. Our collective efforts underscore the ultimate impact of our work: successful surgical outcomes including for children with the most complex cardiac conditions. This first-in-human implant serves to remind us that PECA Labs is

more than just a company – we are a source of life-saving innovation and an industry-leader in pushing technological boundaries to improve patient outcomes.

As always, we at PECA Labs are grateful for your support and interest and we look forward to bringing you more exciting updates in the near future.

All the best,

Doug Bernstein

PECA Labs Chief Executive Officer
